Compare Beyond Meat Inc (BYND) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Beyond Meat Inc vs Viatris Inc — how do they compare? Beyond Meat Inc trades at $0.4 (market cap $215.41M), while Viatris Inc trades at $16.24 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 86.8× Beyond Meat Inc's market cap, and Viatris Inc pays a 2.95% dividend while Beyond Meat Inc pays none. Which is the better fit depends on your goals.
| BYND | VTRS | |
|---|---|---|
Market Cap | $215.41M | $18.69B |
Sector | Consumer Staples | Health |
52-Week High | $3.62 | $17.86 |
52-Week Low | $0.42 | $9.49 |
Enterprise Value | $455.69M | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BYND trades at $0.40, down 22.6% amid a 30:1 reverse stock split announced August 14, 2026. Despite beating Q2 2026 EPS estimates, revenue has declined from $419M in 2022 to $275M in 2025. The stock shows bearish technical signals with oversold RSI readings. Analyst consensus is heavily bearish with 57% sell ratings, reflecting concerns over cash burn and market positioning.
The outlook remains challenging with declining revenues and negative operating cash flow. Investment opportunity exists if turnaround efforts succeed in international markets, but risks include persistent cash burn, competitive pressures, and execution uncertainty. The reverse split addresses listing requirements but doesn't resolve fundamental business challenges.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
